Anti-Mouse CD134 [OX-86] In Vivo Antibody - Low Endotoxin
Introducing the Anti-Mouse CD134 [OX-86] In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody tailored for in vivo applications. This antibody is designed to target the CD134 protein, which is essential in immune response regulation, making it an excellent choice for research in immunology and related fields. With a rat IgG1 isotype, it guarantees high purity and low endotoxin levels (<1.0 EU/mg), making it ideal for various assays including ELISA, flow cytometry, and immunohistochemistry.
Available in multiple sizes, this antibody is formulated in phosphate-buffered saline to ensure stability and efficacy. Enhance your research with this dependable and versatile antibody. CD134, also known as OX40, is a glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily and is predominantly expressed on activated T cells. It plays a crucial role in the immune system by promoting T cell proliferation and survival, thus facilitating an effective immune response.
Product Name:
Anti-Mouse CD134 (Clone OX-86) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0296
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
OX-86
Protein:
CD134
Product Type:
Monoclonal Antibody
Synonyms:
OX-40, TNFRSF4, ACT35
Isotype:
IgG1
Reactivity:
Mouse
Applications:
Act, FC, IHC, In Vivo, WB
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
Act, FC, IHC, In Vivo, WB
Reactivity:
Mouse
Host Species:
Rat
Specificity:
Clone OX-86 reacts with murine CD134 (OX-40, TNFRSF4).
Antigen Distribution:
CD134 is expressed on activated CD4 and CD8 T cells, activated regulatory T cells, B cells, NKT cells, NK cells, and neutrophils.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
CD134 functions as an important immune checkpoint, and its depletion in murine mouse models demonstrate that lack of CD134 expression leads to reduced CD4+ and CD8+ T cells1. When CD134 is bound by its corresponding ligand (OX-40L), an optimal T cell response is generated and plays a significant role in determining the amount of memory T-cells remaining after the immune response1. CD134 has also been found to play an important role in carcinogenesis, as treatment with activating in vivo antibodies against CD134 enhanced tumor growth, suggesting that CD134 is an important tumor suppressor, and its absence disrupts the immune response to tumors2,3.
